Table 3.
Chemotherapy Regimens in Relapsed Ewing’s Sarcoma
| Author | Year of Publication | Study Nature | Number | Chemotherapy | ORR (%) | CR/PR |
|---|---|---|---|---|---|---|
| Temozolomide + Irinotecan | ||||||
| Wagner et al119 | 2007 | Retrospective | 14 | Temozolomide + Irinotecan | 29 | 1/3 |
| Anderson et al190 | 2008 | Retrospective | 25 | Temozolomide + Irinotecan | 64 | 7/9 |
| Casey et al191 | 2009 | Retrospective | 19 | Temozolomide + Irinotecan | 63 | 5/7 |
| Hernández et al192 | 2013 | Retrospective | 8 | Temozolomide + Irinotecan | 37 | 0/3 |
| Raciborska et al193 | 2013 | Retrospective | 22 | Temozolomide + Irinotecan + VCR | 54 | 5/7 |
| Kurucu et al194 | 2015 | Retrospective | 20 | Temozolomide + Irinotecan | 55 | NA |
| Palmerini et al124 | 2018 | Retrospective | 51 | Temozolomide + Irinotecan | 34 | 5/12 |
| Buyukkapu et al195 | 2018 | Retrospective | 15 | Temozolomide + Irinotecan + VCR | 40 | 4/2 |
| Topotecan + Cyclophosphamide | ||||||
| Saylors et al120 | 2001 | II | 17 | Topotecan + Cyclophosphamide | 35 | 2/4 |
| Hunold et al196 | 2006 | Retrospective | 54 | Topotecan + Cyclophosphamide | 32 | 0/16 |
| Farhat et al197 | 2013 | Retrospective | 14 | Topotecan + Cyclophosphamide | 21 | 0/3 |
| Kebudi et al121 | 2013 | Retrospective | 14 | Topotecan + Cyclophosphamide | 50 | 2/5 |
| Gemcitabine + Docetaxel | ||||||
| Fox et al102 | 2012 | II | 14 | Gemcitabine + Docetaxel | 6 | 0/2 |
| Mora et al198 | 2009 | Retrospective | 6 | Gemcitabine + Docetaxel | 67 | 3/1 |
| Tanaka et al122 | 2016 | Retrospective | 4 | Gemcitabine + Docetaxel | 25 | 0/1 |
| Others | ||||||
| Ferrari et al123 | 2009 | Retrospective | 37 | High dose Ifosfamide | 34 | 02/10 |
| van Maldegem et al199 | 2015 | Retrospective | 107 | Etoposide + platinum | 27 | 15/14 |
| Van Winkle et al62 | 2005 | I/II | 22 | Ifosfamide + carboplatin +Etoposide | 48 | 7/14 |
| Devadas et al125 | 2019 | Retrospective | 49 | Tamoxifen + Etoposide + Cyclophosphamide | 59 | 21/8 |
Abbreviations: CR, complete remission; ORR, overall response rate; PR, partial remission; VCR, vincristine.